Cerevel remains committed to developing treatment options for people living with #schizophrenia through our ongoing EMPOWER clinical trial program. Thanks, Nasdaq for joining us in support yesterday! empowerstudies.com
Cerevel Therapeutics’ Post
More Relevant Posts
-
PurMinds is charting an ambitious course with a dynamic two-pronged strategy for success in neurological care and value for our investors: Long-term Vision: We're committed to creating substantial value by advancing a clinical pipeline. Our goal? Confronting neurological disorders with Novel Chemical Entities and innovative therapies, paving the way for a brighter future. Short- and Medium-Term Focus: Leveraging our expertise in psychedelic compound supply for global trials, and licensing our our proprietary formulation technology platform via a US joint venture, prioritizing short and medium-term revenue growth. Explore the details at PurMinds.com 🌐 #NeurologicalInnovation #LeadingTheWay #InvestingNews
To view or add a comment, sign in
-
-
💡 🌱 On 4/20 (#IYKYK), we were joined by Dr. Aaron Boster, neurologist & MS specialist, who diligently answered a variety of questions related to the use of medical marijuana in the setting of neurological conditions. We are so grateful to Dr. Boster for his knowledge, openness, expertise and advocacy for this important topic as well as helping us to continue cultivating a safe space / zero-judgment zone for patients and their loved ones. Watch this insightful webinar in its entirety: https://lnkd.in/ew3664FY
To view or add a comment, sign in
-
Exciting News on the product development front ! In just a few short months, we've successfully processed the the 437 patients tests of our 1st clinical trial. The trial goal was to ascertain the analytical performance of our 1st test (the non-rejection test for patients who have been transplanted with a kidney). A REAL SUCCESS The intensive use of the genic analysis kits and the software has shown that the whole system is indeed very easy to use and robust. AND NOW ? The whole database of results is being transferred to our CRO for statistical analysis. We expect final results to be available by the end of the year. HOW DID WE PULL THAT UP ? Drive and determination from the whole team is the secret. ✔In 1st line we have the lab crew Steven Roblin and Lise Letellier under Marion Cadoux’s leadership and the support of Nicolas Bouler. ✔Critical as well : the action of Caroline Legal under the leadership of Madeleine Rambeau with the support of Olive GUIWUO to get the software ready. #Medtech #laFrenchCare #Nantes #ClinicalTrial
To view or add a comment, sign in
-
Can digital therapeutics amplify happiness? 🥰 For people living with d*pression, positive moments can feel few and far between—but they're still there. Digital therapeutics use evidence-based interventions to reinforce those positive emotions users experience. By prompting users to reflect on recent positive events, it builds gratitude and self-compassion. This in turn helps users feel more hopeful & excited about the future. Watch the full video: https://lnkd.in/g2KpWT9d #digitaltherapeutics #emotionalwellness #mentalhealthinnovation
To view or add a comment, sign in
-
#Technophage is thrilled to share that TZ-161 product is now one step closer to potentially becoming a pioneering repurposed treatment for patients suffering from acute spinal cord injury. This innovative product, currently undergoing clinical trial application in Europe, holds the promise of potentially making an impact on the lives of countless individuals and their families. Acute spinal cord injuries are life-changing events, and TZ-161 could be a ray of hope for those in need. The dedication and hard work of the Technophage team, in collaboration with the CRO team from VectorB2B - Drug Development alongside medical professionals and researchers, are paving the way for this remarkable development. Let's keep our fingers crossed and support this endeavor by spreading the word about TZ-161 and the positive impact it can have on patients' lives. #spinalcordinjury #technophage #partnerships #clinicaltrials
To view or add a comment, sign in
-
-
This Multiple Sclerosis Awareness Month 🧡 , join Vivpro Corp as we illuminate the landscape of regulatory intelligence in this critical area. With our #RIA platform, you can: 1️⃣ Effortlessly search through a multitude of approved products and clinical trials with one intuitive workflow. 2️⃣ Search any indication to discover products that have received "expedited pathways." 3️⃣ Quickly replicate a competitor's Clinical Development Plan and see which trials may have led to approval with RIA's CDP module! 4️⃣ RIA offers quick access to vital Clinical Trials Data. Stay at the forefront of the ever-evolving drug development landscape. ➡ 📞 Schedule a call with us to learn more. https://vivpro.ai/contact #MS #MultipleSclerosis #MSResearch #RegulatoryIntelligence #DrugDevelopment #WisdomWednesday #Vivpro #MorePowerToYou
To view or add a comment, sign in
-
-
Thank you to all of the providers who support us and trust BENEV Exosomes with their patients! A special shoutout to… 💧Jessica Christy, PA-C (@beautyculture.medspa) …for sharing what her experience has been like while using BENEV Exosomes! *Statements made by each provider are of their own experience and not the statements of BENEV Company Inc. #benevskinscience #benevexosomes #exosomes #exosomeregenerativecomplex #exocobio #benev+exocobio #exosometechnology *Disclaimer: BENEV Exosome Regenerative Complexes are not drug products. They are not intended to prevent, treat, or cure diseases or medical conditions. They are not intended to be injected or delivered intravenously.
To view or add a comment, sign in
-
By gaining a deeper understanding of cytokine responses, we empower developers to fine-tune their products, ensuring they're optimized for maximum effectiveness before reaching clinical trials. Read the full white paper here 📄 https://bit.ly/3nhuPEZ #WoundCare
To view or add a comment, sign in
-
-
A new era for @KinesysConsulting! Joining @Clinigen strengthens our capabilities and allows us to make a significant contribution to accelerating the development of life-saving therapies. #RegulatoryAffairs #PatientAccess #DrugLifecycle
To view or add a comment, sign in